Your browser doesn't support javascript.
loading
Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Thomson, Christopher G; Le Grand, Darren; Dowling, Mark; Beattie, David; Elphick, Lucy; Faller, Michael; Freeman, Mark; Hardaker, Elizabeth; Head, Victoria; Hemmig, Rene; Hill, Johan; Lister, Andrew; Pascoe, David; Rieffel, Sebastien; Shrestha, Binesh; Steward, Oliver; Zink, Florence.
Afiliação
  • Thomson CG; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK. Electronic address: chris.thomson@pharmaron-uk.com.
  • Le Grand D; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Dowling M; Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Beattie D; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Elphick L; Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Faller M; Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.
  • Freeman M; Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Hardaker E; Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Head V; Metabolism and Pharmacokinetics, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Hemmig R; Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.
  • Hill J; Respiratory Disease Area, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Lister A; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Pascoe D; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Rieffel S; Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.
  • Shrestha B; Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.
  • Steward O; Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK.
  • Zink F; Department of Chemical Biology and Therapeutics, Novartis Institutes For Biomedical Research, Basel, Switzerland.
Bioorg Med Chem Lett ; 31: 127663, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33160025
ABSTRACT
A series of inhibitors of Autotaxin (ATX) have been developed from a high throughput screening hit, 1a, which shows an alternative binding mode to known catalytic site inhibitors. Selectivity over the hERG channel and microsomal clearance were dependent on the lipophilicity of the compounds, and this was optimised by reduction of clogD whilst maintaining high affinity ATX inhibition. Compound 15a shows good oral exposure, and concentration dependent inhibition of formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic (PK/PD) experiments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tetrazóis / Cinamatos / Diester Fosfórico Hidrolases / Inibidores Enzimáticos / Desenvolvimento de Medicamentos / Amidas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tetrazóis / Cinamatos / Diester Fosfórico Hidrolases / Inibidores Enzimáticos / Desenvolvimento de Medicamentos / Amidas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2021 Tipo de documento: Article